Imexhs Ltd · ASX:IME
Imexhs — Shareholder Meeting (May 2026)
51 slides from Imexhs's shareholder meeting presentation, May 20, 2026
Slide 1: 2026 Annual General Meeting – Chairman and CEO Addresses
20 May 2026 ASX ANNOUNCEMENT 2026 Annual General Meeting – Chairman and CEO Addresses In accordance with ASX Listing Rule 3.13, attached are the Chairman and CEO Addresses together with the presentation slides, which will be delivered at the IMEXHS Limited (ASX: IME) (Company) Annual General Meeting
Slide 2: Chairman's Address
IMEXHS Limited Annual General Meeting 20 May 2026 Chairman’s Address Let me now give you my summary of what was achieved in 2025 and my view of the status and opportunity for the company as we move through 2026. As I said in our 2025 Annual Report, IMEXHS made meaningful progress across several fron
Slide 3: Chairman's Address: Aquila+ and cash management
Despite these gains, IMEXHS will continue to manage cash tightly through 2026. We remain a small company with significant ambition. Accelerating growth requires careful balancing of cash resources with investment in sales, marketing, and the working capital needed to support expansion. This will be
Slide 4: Broader political and economic environment
The broader political and economic environment has been challenging. Colombia, a key market, continues to face financial pressure induced by government across insurers and hospitals. Presidential elections are scheduled for Q2 2026. A change of government is expected to release the pressure on the h
Slide 5: CEO Address: Latin America home market and 2025 results
Our home market is Latin America. My co-founder and I built this Company here. Our deepest clinical relationships are here. And the structural need for what we do is most acute here. That regional expertise is not easily replicated — it is our primary competitive advantage. Looking at the operationa
Slide 6: Oncolife contract and Q1 momentum
The Oncolife contract in Colombia illustrates the model working as intended — high-complexity services plus software, supported by IMEXHS Enterprise RIS/PACS, Patient Portal and selected AI layers. That contract grew from an expected $1.4 million in ARR to $2.1 million in actuals. On the large oppor
Slide 7: Proprietary AI agents
Agent four — Non-Attendance Alerts: live. Monitors every study and flags cases at risk of exceeding their SLA threshold. Reduces overlooked cases and medico-legal exposure. Agent five — RV Mentor, our AI co-pilot for the radiologist. Live today: contextual medical queries, report evaluation, image a
Slide 8: Annual General Meeting
Annual General Meeting 20 May 2026
Slide 9: Agenda
Agenda 2026 AGM 1. Introductions 2. Chairman's Address 3. CEO's Address 4. Business of Meeting 5. Resolutions & Proxy Vote Results 2
Slide 10: Board of Directors
Board of Directors Doug Flynn Carlos Palacio Dr Doug Lingard Damian Banks Dr German Arango Non-Executive Non-Executive Non-Executive Non-Executive CEO & Managing Chairman Director Director Director Director 3
Slide 11: Automic Group: Investor sign in
42 AUTOMIC GROUP Manage Your Holdings & Securities. VOTING INTENTION, Will you be registering to vote? ‘The lve stream will become avaliable ‘once intention reg gistered 4g AUTOMIC GROUP” 7 Investor sign in 02 03 Login & Registration Go to https://investor.automic.com.au/#/home Under Meetings menu,
Slide 12: Registration and voting instructions
Registration G Preferred name: Ethan Brown ¢ © Key Documents D Ask a Question G Submit Votes 4g AUTOMIC GROUP” Voting Instructions Once registered and voting has opened, click on the “Voting” dropdown Select either the “Full” or “Allocate” and then your voting direction for each resolution Follow th
Slide 13: Ask a Question
DP Ask a Question My Questions [D rexrouestion | Q versa question 4g AUTOMIC GROUP” Ask a Question Click on the “Ask a Question” dropdown, then “Ask Question” Choose Text Question or Verbal Question Type your question then select the relevant resolution and holding. Once done click “Submit Question”
Slide 14: Chairman's Address
Chairman's Address Doug Flynn 4
Slide 15: CEO's Address
CEO's Address Dr German Arango 8
Slide 16: Management Team
Management Team Dr German Arango Reena Minhas Daniel Laverde Dr Jorge Marin Chief Medical Officer CEO & Managing Director Chief Financial Officer Chief Operations Officer & Co-Founder Mario Huyo Dr Sandra Niño Elizabeth Mendez Operations Manager & Sales Director Medical Director Contract Audit 9
Slide 17: One Company with two businesses democratising medical imaging expertise
10 One Company with two businesses aimed at democratising access to medical imaging expertise Software Business Radiology Services Medical imaging software (RIS, Radiology services, primarily PACS, universal viewer, AI) in Colombia 10
Slide 18: Operational Performance
11 Operational Performance Key Platform Metrics Installed Sites 564 566 8.3M 556 Studies Reported 549 546 521 525 3.6M 518 Portal Users – active patients with digital access 511 8.2M Portal Sessions – 2.3x avg sessions per user Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 NPS: 42.7 Year 1 b
Slide 19: FY25 Financial Highlights
12 FY25 Financial Highlights Revenue Annual Recurring Underlying Revenue (ARR) EBITDA2 Up 10% yoy Up 16% yoy Up 6% on a constant $29.0m Up 7% on a constant $34.8m Up vs $0.5m in pcp $1.6m currency basis1 currency basis H2 EBITDA Cash Debt Up vs $0.3m in H1 FY25 $1.3m vs $2.1m at $3.3m vs $1.2m at $0
Slide 20: FY25 Results at the Top End of Guidance
13 FY25 Results at the Top End of Guidance ➢ Revenue of $29.0m Up from $26.5m or 10% vs pcp and ahead of revenue guidance of $27.5m–$28.2m ➢ Underlying EBITDA of $1.6m Up vs $0.5m in pcp and at the top end of guidance of $1.3m–$1.6m ➢ H2 FY25 Underlying EBITDA of $1.3m Demonstrating clear earnings m
Slide 21: FY25 Business Unit Results
14 FY25 Business Unit Results ➢ Software primarily relates to sales of IMEXHS $M Software Radiology Corporate Total Enterprise and growing IMEXHS Cloud business ➢ Revenue up 12% vs pcp | ARR up 19% vs pcp Revenue 10.0 19.0 - 29.0 ➢ Underlying EBITDA $3.0m (30% margin) vs $3.2m (36% margin) in pcp Un
Slide 22: Progress in ARR
15 Progress in ARR ARR at 31 Dec-25 • $34.8m, up 16% vs pcp: ➢ $11.8m from Software, up 19% vs pcp ($9.9m); and ➢ $23.0m from Radiology services, up 14% vs pcp ($20.1m) (1) Constant currency basis assumes that historical results at each year end are converted at the 31 Dec-25 exchange rate. This rem
Slide 23: Financial turning point: positive EBITDA, stronger cash collection, lower debt
16 Financial turning point: positive EBITDA, stronger cash collection, lower debt What we did What it delivered • Tightened credit terms and collections • Revenue: $29.0m, up 10% vs pcp. discipline; focused on on-time payors. • Underlying EBITDA: H2 $1.3m vs H1 • Cost program in motion (AI agents- $
Slide 24: Software Business Highlights - IMEXHS
17 Software Business Highlights - IMEXHS ➢ Pipeline strengthened after enhanced inbound/outbound marketing strategy. ➢ Key wins/renewals: • Salud Total Group (Colombia): 2 enterprise renewals expanding value via cloud migration + broader functionality + additional services ($348k NARR aggregate). •
Slide 25: Radiology Services - RIMAB
18 Radiology Services - RIMAB ➢ Opportunistic growth strategy, larger, strong margin, credit worthy clients. ➢ New contract: Oncolife (Colombia) high-complexity services, grew from ARR expected of ~$1.4m, to $2.1m actuals. This contract includes services + software, supported by IMEXHS Enterprise RI
Slide 26: Q1 FY26 Business Update – Strong Start
19 Q1 FY26 Business Update – Strong Start $7.9m $0.8m $34.8m $2.5m Q1 Revenue Q1 EBITDA ARR Cash Up 13% vs pcp vs $0.1m in pcp Up 11% vs pcp at 31 Mar 2026 • Both revenue and earnings ahead of plan • Software Partner Programme contributed 60% of software NARR for the quarter • RIMAB delivered record
Slide 27: Our focus right now
Our focus right now iIMexXHS 20
Slide 28: Aquila+ Agentic AI Platform
21 Aquila+ Agentic AI Platform Five proprietary AI agents embedded across the full radiology workflow What it is Why it is differentiated Commercial impact An AI-native platform where five No competitor addresses the full Projected 80% reduction in call-centre proprietary agents operate workflow. Ea
Slide 29: The Five Agents – Full Workflow Automation
22 The Five Agents – Full Workflow Automation 1 2 3 4 5 Appointment Study Auto- Non-Attendance RV Mentor Scheduling Prioritisation Distribution Alerts (AI Co-Pilot) Live Final Testing Live Live Live Reads medical orders & Evaluates radiologist Contextual queries, report insurance authorisations; Ana
Slide 30: Aquila+ AI agents ready; partners scaling; pipeline strengthening
23 Aquila+ AI agents ready; partners scaling; pipeline strengthening • Product-ready for scale: Aquila+ live across teleradiology, clinics and hospital groups (agents driving efficiency and quality , one-click tenant activation, 99.9% uptime). • Go-to-market discipline: strengthened partner channel,
Slide 31: Aquila+: agentic AI platform that lowers total cost-to-serve
24 Aquila+ : agentic AI platform that lowers total cost-to-serve → New agentic approach to critical → Faster from scan to → ~70% lower marginal points of the workflow. the answer: shorter report cost-to-serve per new turn around and SaaS tenant; 1-click tenant → ~40% faster worklists; fewer clicks p
Slide 32: Expand margins through pricing discipline, automation and mix
25 Expand margins through pricing discipline, automation and mix Pricing & Terms Automation & Unit Portfolio Discipline Cost & Mix → Apply improved terms & → AI-orchestrated → Prioritise higher-margin conditions and workflows (already software modules and segmentation. reducing service costs). enter
Slide 33: Collections up, cash stable, debt down - discipline sustained
26 Collections up, cash stable, debt down - discipline sustained Operating Discipline Outcomes • Enhanced credit controls, proactive • Net operating cash inflow of $0.6m, up collections, and structured repayment from cash outflow of ($0.6m) in pcp. arrangements where appropriate. • Debt reduced to $
Slide 34: Outlook & Priorities FY26
27 Outlook & Priorities FY26 Scale Software: Accelerated growth with multi-front improvements; Aquila+ to be the preferred radiology platform across the region. Pipeline & GTM: Strengthened with new marketing strategy; partner channel increasing contribution to NARR; good traction in Mexico. AI Agen
Slide 35: FY26 Guidance
28 FY26 Guidance The Company expects to: Exceed FY25 Underlying EBITDA Be cash positive for FY26 Grow software revenue at a faster rate than in FY25 See more of the growth in Revenue, Earnings and Cash in H2 The Company expects to provide more specific guidance at the H1 FY26 results in August 2026.
Slide 36: Thank You
imexHS . * THANK YOU
Slide 37: Business of Meeting
imexHS Business of Meeting
Slide 38: Resolutions & Proxy Vote Results
Resolutions & Proxy Vote Results 31
Slide 39: Financial Report Q&A
Financial Report To receive the financial report of the Company and the reports of the Directors and of the Auditors for the financial year ended 31 December 2025. Q&A 32
Slide 40: Resolution 1: Remuneration Report
Resolution 1: Remuneration Report “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 31 December 2025 as disclosed in the Company’s Annual Report be adopted.” For Against Open 3,663,194 93,533 559,570 84
Slide 41: Resolution 2: Re-election of Director – Mr Douglas Flynn
Resolution 2: Re-election of Director – Mr Douglas Flynn “That, for the purpose of Article 6.3(c) of the Constitution, ASX Listing Rules 14.4 and 14.5, and for all other purposes, Mr Douglas Flynn, a Director, retires by rotation, and being eligible, is re- elected as a Director of the Company.” For
Slide 42: Resolution 3: Grant of Options to the CEO under the LTIP
Resolution 3: Grant of Options to the CEO under the Long-Term Incentive Plan (LTIP) “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 357,000 Options to the Managing Director & CEO, Dr German Arango, under the LTIP on the terms and condit
Slide 43: Resolution 4: Approval of 10% Share Placement Capacity
Resolution 4: Approval of 10% Share Placement Capacity "That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the Company having additional capacity to issue Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) (10% Sh
Slide 44: Resolution 5: Grant of Options to the CEO for Short-Term Incentive Payment
Resolution 5: Grant of Options to the CEO for Short-Term Incentive Payment “That, for the purposes of ASX Listing Rule 10.11 and all other purposes, the Shareholders approve the grant of 121,977 Options to the Managing Director & CEO, Dr German Arango, on the terms and conditions set out in the Expl
Slide 45: Resolution 6: CEO Salary Sacrifice
Resolution 6: CEO Salary Sacrifice “That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, Shareholders approve the grant of 266,438 Options to the Managing Director and Chief Executive Officer, Dr German Arango, in lieu of the payment of a portion of his cash salary for the pe
Slide 46: Resolution 7: Issue of Shares in Lieu of Fees to Mr Damian Banks
Resolution 7: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Mr Damian Banks “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the non-executive Director, Mr Damian Banks, in lieu of the payment of certain
Slide 47: Resolution 8: Issue of Shares in Lieu of Fees to Mr Douglas Flynn
Resolution 8: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Mr Douglas Flynn “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the non-executive Director, Mr Douglas Flynn, in lieu of the payment of certai
Slide 48: Resolution 9: Issue of Shares in Lieu of Fees to Dr Douglas Lingard
Resolution 9: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Dr Douglas Lingard “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the non-executive Director, Dr Douglas Lingard, in lieu of the payment of ce
Slide 49: Resolution 10: Issue of Shares in Lieu of Fees to Mr Carlos Palacio
Resolution 10: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Mr Carlos Palacio “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the non-executive Director, Mr Carlos Palacio, in lieu of the payment of cer
Slide 50: Thank You
imexHS . * THANK YOU
Slide 51: Annual General Meeting
Annual General Meeting 20 May 2026 44